The Company had $403.4 million in cash, cash equivalents, and investments as of September 30…”We are proud of the progress made in the third quarter of 2024 to advance our investigational allogeneic cell products in key “firsts” – our first-line consolidation trial in large B-cell lymphoma with cema-cel, ALLO-316 as the first allogeneic CAR T product candidate to demonstrate positive results in solid tumors, and the first CD19/CD70 dual CAR T candidate specifically designed for autoimmune disease,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “We believe these efforts have the potential to redefine treatment paradigms, tailoring therapies to meet the unique needs of large patient populations, and enabling broader real-world adoption. Allogene remains dedicated to driving innovation that improves outcomes for patients with both cancer and autoimmune diseases.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene announces Phase 1 data on ALLO-316 in advanced RCC
- Allogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings
- Allogene Therapeutics receives FDA RMAT designation for ALLO-316
- Is ALLO a Buy, Before Earnings?
- Artiva Biotherapeutics appoints Alison Moore, Ph.D., to Its Board of Directors